Melvin Berger - Academia.edu (original) (raw)
Papers by Melvin Berger
Blood
Neutrophil (PMN) activation is associated with increased surface expression of several membrane p... more Neutrophil (PMN) activation is associated with increased surface expression of several membrane proteins that are translocated from intracellular pools. Indirect evidence suggests that the intracellular storage pools of complement receptor type 1 (CR1) in resting PMN are distinct from traditional granules and may be the secretory vesicles in which albumin is also stored, but it is not known if this compartment is homogeneous or heterogeneous. To isolate and characterize the CR1-containing vesicles, we used antibodies against unique sequences in the cytoplasmic tail of CR1. Affinity-purified IgG was used to adsorb CR1 storage vesicles from the light membrane fraction (γ-band) of nitrogen cavitates of resting PMN. The immunoadsorbent could quantitatively remove the CR1-containing vesicles, whereas control adsorbents with nonimmune IgG showed no specific binding of CR1. Immunoblots of specifically isolated vesicles also showed enrichment of albumin, decay-accelerating factor, FcγRIII, ...
American Journal of Transplantation
Despite significant advances in surgical technique and immunosuppression, challenges continue to ... more Despite significant advances in surgical technique and immunosuppression, challenges continue to restrict the number of transplants. Although the number of transplants performed each year in the United States is increasing, the number of people on waiting lists has nearly doubled in the past 15 years. 1 Improving the viability of donor organs by reducing the damage caused by ischemia-reperfusion injury (IRI) and activation of the innate immune system are thus key areas of ongoing research. Alpha-1-antitrypsin (AAT) is a serine protease inhibitor and acute phase reactant produced mainly by the liver that limits tissue damage caused by neutrophil elastase and other extracellular enzymes. 2-4 Consistent with this role, plasma concentrations of AAT can increase up to 4-fold in response to inflammatory stimuli. Mutations in AAT can cause emphysema due to deficiency in circulating AAT, and/or liver disease likely due to a "misfolded protein response." 2-4 AAT-deficient patients may also experience extrapulmonary pathologies, particularly panniculitis
Transfusion
* In this table, data from Wu et al. 42 is for products made from US plasma only.
Immunotherapy, Jan 16, 2018
Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chro... more Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88% of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, ...
Journal of the peripheral nervous system : JPNS, Jan 23, 2018
Despite the well-recognized importance of immunoglobulin therapy individualization during the tre... more Despite the well-recognized importance of immunoglobulin therapy individualization during the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), the pathway to best achieve optimization is unknown. There are many pharmacokinetic and immunobiologic variables that can potentially influence the appropriateness of any individual therapy. Although identification of specific autoantibodies and their targets has only been accomplished in a minority of patients with CIDP, already the diagnostic and treatment implications of specific autoantibody detection are being realized. Individual variability in IgG pharmacokinetic properties including IgG catabolic rates and distribution, as well as the IgG level necessary for disease control also require consideration during the optimization process. For optimization to be successful there must be a measure of treatment response that has a clinically meaningful interpretation. There are currently available well-defined and validat...
Respiratory medicine, 2017
More than half of all primary immune deficiency diseases (PIDD) affect antibody production and ar... more More than half of all primary immune deficiency diseases (PIDD) affect antibody production and are well known as causes of recurrent sinusitis and lung infections. Chronic and recurrent infections of the upper and/or lower airways can contribute to inflammatory and obstructive processes in the lower airways which are initially reversible and considered "asthma", but can eventually cause irreversible remodeling and chronic obstructive pulmonary disease (COPD). Conversely, several lines of evidence suggest that many patients who present with a diagnosis of asthma have an increased incidence of infection, suggesting underlying host-defense defects. Asthma and respiratory infections in the first decades of life are recognized as risk factors for development of COPD, but when patients present with COPD as adults, underlying primary immune deficiency disease may be unrecognized. Detection of PIDD as a potentially treatable underlying contributor to recurrent/acute exacerbations ...
Blood Reviews
Immunoglobulins are used to prevent or reduce infection risk in primary immune deficiencies and i... more Immunoglobulins are used to prevent or reduce infection risk in primary immune deficiencies and in settings which exploit its anti-inflammatory and immune-modulatory effects. Rigorous proof of immunoglobulin efficacy in persons with lympho-proliferative neoplasms, plasma cell myeloma, and persons receiving hematopoietic cell transplants is lacking despite many clinical trials. Further, there are few consensus guidelines or algorithms for use in these conditions. Rapid development of new therapies targeting B-cell signaling and survival pathways and increased use of chimeric antigen receptor T-cell (CAR-T) therapy will likely result in more acquired deficiencies of humoral immunity and infections in persons with cancer. We review immunoglobulin formulations and discuss efficacy and potential adverse effects in the context of preventing infections and in graft-versus-host disease. We suggest an algorithm for evaluating acquired deficiencies of humoral immunity in persons with hematologic neoplasms and recommend appropriate use of immunoglobulin therapy.
American Journal of Respiratory and Critical Care Medicine, May 1, 2002
American Journal of Respiratory Cell and Molecular Biology, 2007
Annals of Allergy Asthma Immunology Official Publication of the American College of Allergy Asthma Immunology, Mar 1, 2008
Clin Rev Allergy Immunol, 1991
Although the relationship between the basic cellular defect in Cystic Fibrosis (CF) and the facto... more Although the relationship between the basic cellular defect in Cystic Fibrosis (CF) and the factors that predispose the CF patient to colonization with Pseudornonas aeruginosa remain undefined, it
Allergy and Asthma Proceedings, 2002
Journal of Allergy and Clinical Immunology, 1996
Journal of Allergy and Clinical Immunology, Feb 1, 2011
Curr Opin Infect Dis, 1991
Immunology and Allergy Clinics of North America, 2008
This article summarizes the guidelines for using replacement therapy in the management of patient... more This article summarizes the guidelines for using replacement therapy in the management of patients who have primary antibody deficiency.
N Engl J Med, 1983
... ABSENCE OF THE THIRD COMPONENT OF COMPLEMENT Melvin Berger, MD, Ph.D., James E. Balow, MD, Cu... more ... ABSENCE OF THE THIRD COMPONENT OF COMPLEMENT Melvin Berger, MD, Ph.D., James E. Balow, MD, Curtis B. Wilson, MD, and Michael M. Frank, MD THE third component of complement (C3) is criti-cally involved in host defense and the mainte-nance of normal ...
Methods in Enzymology, 1990
Blood
Neutrophil (PMN) activation is associated with increased surface expression of several membrane p... more Neutrophil (PMN) activation is associated with increased surface expression of several membrane proteins that are translocated from intracellular pools. Indirect evidence suggests that the intracellular storage pools of complement receptor type 1 (CR1) in resting PMN are distinct from traditional granules and may be the secretory vesicles in which albumin is also stored, but it is not known if this compartment is homogeneous or heterogeneous. To isolate and characterize the CR1-containing vesicles, we used antibodies against unique sequences in the cytoplasmic tail of CR1. Affinity-purified IgG was used to adsorb CR1 storage vesicles from the light membrane fraction (γ-band) of nitrogen cavitates of resting PMN. The immunoadsorbent could quantitatively remove the CR1-containing vesicles, whereas control adsorbents with nonimmune IgG showed no specific binding of CR1. Immunoblots of specifically isolated vesicles also showed enrichment of albumin, decay-accelerating factor, FcγRIII, ...
American Journal of Transplantation
Despite significant advances in surgical technique and immunosuppression, challenges continue to ... more Despite significant advances in surgical technique and immunosuppression, challenges continue to restrict the number of transplants. Although the number of transplants performed each year in the United States is increasing, the number of people on waiting lists has nearly doubled in the past 15 years. 1 Improving the viability of donor organs by reducing the damage caused by ischemia-reperfusion injury (IRI) and activation of the innate immune system are thus key areas of ongoing research. Alpha-1-antitrypsin (AAT) is a serine protease inhibitor and acute phase reactant produced mainly by the liver that limits tissue damage caused by neutrophil elastase and other extracellular enzymes. 2-4 Consistent with this role, plasma concentrations of AAT can increase up to 4-fold in response to inflammatory stimuli. Mutations in AAT can cause emphysema due to deficiency in circulating AAT, and/or liver disease likely due to a "misfolded protein response." 2-4 AAT-deficient patients may also experience extrapulmonary pathologies, particularly panniculitis
Transfusion
* In this table, data from Wu et al. 42 is for products made from US plasma only.
Immunotherapy, Jan 16, 2018
Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chro... more Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88% of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, ...
Journal of the peripheral nervous system : JPNS, Jan 23, 2018
Despite the well-recognized importance of immunoglobulin therapy individualization during the tre... more Despite the well-recognized importance of immunoglobulin therapy individualization during the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), the pathway to best achieve optimization is unknown. There are many pharmacokinetic and immunobiologic variables that can potentially influence the appropriateness of any individual therapy. Although identification of specific autoantibodies and their targets has only been accomplished in a minority of patients with CIDP, already the diagnostic and treatment implications of specific autoantibody detection are being realized. Individual variability in IgG pharmacokinetic properties including IgG catabolic rates and distribution, as well as the IgG level necessary for disease control also require consideration during the optimization process. For optimization to be successful there must be a measure of treatment response that has a clinically meaningful interpretation. There are currently available well-defined and validat...
Respiratory medicine, 2017
More than half of all primary immune deficiency diseases (PIDD) affect antibody production and ar... more More than half of all primary immune deficiency diseases (PIDD) affect antibody production and are well known as causes of recurrent sinusitis and lung infections. Chronic and recurrent infections of the upper and/or lower airways can contribute to inflammatory and obstructive processes in the lower airways which are initially reversible and considered "asthma", but can eventually cause irreversible remodeling and chronic obstructive pulmonary disease (COPD). Conversely, several lines of evidence suggest that many patients who present with a diagnosis of asthma have an increased incidence of infection, suggesting underlying host-defense defects. Asthma and respiratory infections in the first decades of life are recognized as risk factors for development of COPD, but when patients present with COPD as adults, underlying primary immune deficiency disease may be unrecognized. Detection of PIDD as a potentially treatable underlying contributor to recurrent/acute exacerbations ...
Blood Reviews
Immunoglobulins are used to prevent or reduce infection risk in primary immune deficiencies and i... more Immunoglobulins are used to prevent or reduce infection risk in primary immune deficiencies and in settings which exploit its anti-inflammatory and immune-modulatory effects. Rigorous proof of immunoglobulin efficacy in persons with lympho-proliferative neoplasms, plasma cell myeloma, and persons receiving hematopoietic cell transplants is lacking despite many clinical trials. Further, there are few consensus guidelines or algorithms for use in these conditions. Rapid development of new therapies targeting B-cell signaling and survival pathways and increased use of chimeric antigen receptor T-cell (CAR-T) therapy will likely result in more acquired deficiencies of humoral immunity and infections in persons with cancer. We review immunoglobulin formulations and discuss efficacy and potential adverse effects in the context of preventing infections and in graft-versus-host disease. We suggest an algorithm for evaluating acquired deficiencies of humoral immunity in persons with hematologic neoplasms and recommend appropriate use of immunoglobulin therapy.
American Journal of Respiratory and Critical Care Medicine, May 1, 2002
American Journal of Respiratory Cell and Molecular Biology, 2007
Annals of Allergy Asthma Immunology Official Publication of the American College of Allergy Asthma Immunology, Mar 1, 2008
Clin Rev Allergy Immunol, 1991
Although the relationship between the basic cellular defect in Cystic Fibrosis (CF) and the facto... more Although the relationship between the basic cellular defect in Cystic Fibrosis (CF) and the factors that predispose the CF patient to colonization with Pseudornonas aeruginosa remain undefined, it
Allergy and Asthma Proceedings, 2002
Journal of Allergy and Clinical Immunology, 1996
Journal of Allergy and Clinical Immunology, Feb 1, 2011
Curr Opin Infect Dis, 1991
Immunology and Allergy Clinics of North America, 2008
This article summarizes the guidelines for using replacement therapy in the management of patient... more This article summarizes the guidelines for using replacement therapy in the management of patients who have primary antibody deficiency.
N Engl J Med, 1983
... ABSENCE OF THE THIRD COMPONENT OF COMPLEMENT Melvin Berger, MD, Ph.D., James E. Balow, MD, Cu... more ... ABSENCE OF THE THIRD COMPONENT OF COMPLEMENT Melvin Berger, MD, Ph.D., James E. Balow, MD, Curtis B. Wilson, MD, and Michael M. Frank, MD THE third component of complement (C3) is criti-cally involved in host defense and the mainte-nance of normal ...
Methods in Enzymology, 1990